Century Therapeutics Future Growth

Future criteria checks 2/6

Century Therapeutics's earnings are forecast to decline at 3.4% per annum while its annual revenue is expected to grow at 50% per year. EPS is expected to grow by 7.1% per annum.

Key information

-3.4%

Earnings growth rate

7.1%

EPS growth rate

Biotechs earnings growth	23.5%
Revenue growth rate	50.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Apr 2024

Recent future growth updates

Recent updates

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

Earnings and Revenue Growth Forecasts

NasdaqGS:IPSC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	21	-163	N/A	N/A	2
12/31/2025	23	-138	N/A	N/A	5
12/31/2024	1	-137	N/A	N/A	5
12/31/2023	2	-137	-102	-88	N/A
9/30/2023	2	-129	-104	-85	N/A
6/30/2023	5	-127	-121	-96	N/A
3/31/2023	6	-125	-133	-102	N/A
12/31/2022	5	-131	-17	14	N/A
9/30/2022	5	-127	-28	13	N/A
6/30/2022	2	-123	-34	13	N/A
3/31/2022	1	-115	-27	20	N/A
12/31/2021	N/A	-96	-134	-89	N/A
9/30/2021	N/A	-83	-108	-78	N/A
6/30/2021	N/A	-70	-82	-63	N/A
3/31/2021	N/A	-62	-66	-57	N/A
12/31/2020	N/A	-54	-51	-41	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPSC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPSC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPSC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPSC's revenue (50% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: IPSC's revenue (50% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IPSC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Century Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates decrease by 86%, EPS upgraded

Consensus revenue estimates fall by 32%

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

Price target decreased by 9.2% to US$17.89

Recent updates

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Price target decreased by 9.2% to US$17.89

Price target decreased by 8.6% to US$18.00

Chief Scientific Officer recently sold US$55k worth of stock

Chief Scientific Officer exercised options and sold US$351k worth of stock

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Elipse-1 Trial Evaluating Cnty-101 in Relapsed or Refractory Cd19 Positive B-Cell Lymphomas

Price target decreased to US$20.30

Consensus revenue estimates increase by 26%

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Preclinical Data At the SITC 37Th Annual Meeting and Provides Pipeline Updates

Price target decreased to US$22.44

Casdin Capital Engages in Discussions with Century Therapeutics

Century Therapeutics, Inc. Announces Board Changes

Century Therapeutics, Inc. Receives Study May Proceed Notification from FDA for CNTY-101

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Consensus revenue estimates fall by 20%

Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 2,133%

High number of new and inexperienced directors

Century Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Data At the 63Rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies